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Abstract 15 
Bioactive food peptides are encrypted within the source protein but can exert 16 
physiological properties once released by enzymatic hydrolysis during gastrointestinal transit, 17 
fermentation or maturation during food processing, or proteolysis by food-grade enzymes derived 18 
from microorganisms or plants. Among the bioactive food peptides, those with antihypertensive 19 
activity are receiving special attention due to the high prevalence of hypertension in the Western 20 
countries and its role in cardiovascular diseases. This paper reviews the current literature on 21 
antihypertensive food peptides, focusing on the existing methodologies for their production, such 22 
as enzymatic hydrolysis, fermentation and genetic recombination in bacteria. This paper also 23 
evaluates the structure/activity relationship of angiotensin-converting enzyme (ACE) inhibitory 24 
peptides, as well as their bioavailability, physiological effects demonstrated by both in vitro and 25 
in vivo assays, and the existence of mechanisms of action other than ACE inhibition. Finally, 26 
current reported strategies for incorporation of antihypertensive peptides in foods and their 27 
effects on both availability and activity of these peptides are revised in this manuscript.   28 
 29 
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1. Introduction 32 
 In recent years, increasing epidemiological evidence is linking the prevalence of diseases, 33 
such as cardiovascular disease, obesity, hypertension, diabetes, and even cancer to dietary factors. 34 
Manufacture of new foods termed functional foods is emerging in response to the increased 35 
perception about the relation of food and health. A functional food is generally any food which 36 
can provide a health benefit to one or more bodily functions beyond that of basic nutrition [1]. 37 
Recently, it has been recognized that apart from their basic nutritional role, many dietary proteins 38 
contain, encrypted within their primary structure, different peptide sequences that exert beneficial 39 
effects upon human health once released by digestive enzymes during gastrointestinal transit or 40 
by fermentation or ripening during food processing. Bioactive peptides range in size from 2 to 50 41 
amino acid residues and exhibit different activities, such as antimicrobial, antioxidant, 42 
antithrombotic, antihypertensive, immunomodulatory, opioid, and antiproliferative activities, 43 
among others [2-4], affecting the major body systems – namely, the cardiovascular, digestive, 44 
endocrine, immune and nervous systems. The potential of these bioactive peptides to reduce the 45 
risk of chronic diseases and to promote human health has aroused increasing scientific and 46 
commercial interest over the past decade [5]. 47 
High blood pressure or hypertension, which is estimated to affect one third of the Western 48 
population [6], is a risk factor for cardiovascular diseases including coronary heart disease, 49 
peripheral artery disease and stroke. In view of its high prevalence and importance, changes in 50 
life-style, dietary approaches and pharmacological treatments are broadly applied to treat 51 
hypertension. It has been recognized that nutritional factors play a significant role in the 52 
prevention and/or treatment of hypertension, and therefore, efforts are being put into the 53 
production of foods with antihypertensive activity. Angiotensin-converting enzyme (ACE, EC 54 
3.4.15.1) is one of the main regulators of blood pressure through its action on two body systems. 55 
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Firstly, ACE forms part of the rennin-angiotensin system (RAS), converting angiotensin I to a 56 
potent vasoconstrictor, angiotensin II, which also induces the release of aldosterone and therefore, 57 
increases the sodium concentration and blood pressure. ACE also takes part of the kinin-kalicrein 58 
system as it hydrolyzes bradykinin, which has a vasodilator action. By inhibiting this enzyme, 59 
bioactive peptides have been shown to lower blood pressure in animal and clinical studies. First 60 
ACE inhibitors were discovered in snake venom. Currently, different ACE inhibitors, such as 61 
Captopril and Enalapril, are being extensively used to treat essential hypertension. However, their 62 
undesirable effects, such as hypotension, cough, increased potassium levels, reduced renal 63 
function, angioedema, etc. [7], have promoted the search of ACE inhibitory peptides derived 64 
from food natural sources. To date, milk from different species is the main source of ACE 65 
inhibitory peptides [3, 8, 9]. Other animal protein sources of these peptides are muscle [10], 66 
ovalbumin [11], blood [12], and fish proteins [13, 14]. Plant protein sources include, among 67 
others, pea [15], garlic [16], rice [17], soybean [18, 19], wheat [20], and Amaranth proteins [21].  68 
This article reviews current literature on the subject of ACE inhibitory and 69 
antihypertensive peptides, their structure-activity relationship, mechanism of action and 70 
bioavailability. Evaluation of their activity in humans as well as their possible incorporation into 71 
food products will be also covered.  72 
  73 
2. Release and identification of antihypertensive peptides 74 
Biologically active peptides can be released from their parent protein by enzymatic 75 
hydrolysis during gastrointestinal digestion, fermentation or maturation during food processing or 76 
proteolysis by food-grade enzymes derived from microorganisms, animals or plants [22]. If the 77 
peptidic sequence is known, it is also possible to synthesize the peptide by chemical or enzymatic 78 
synthesis or by recombinant DNA technology [23].  79 
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2.1. Gastrointestinal digestion 80 
It has been recognized that dietary proteins and peptides are susceptible to hydrolysis 81 
during the different stages of gastrointestinal digestion, namely ingestion, digestion and 82 
absorption [24]. Once ingested, these proteins and peptides are subjected to hydrolysis by 83 
different enzymes present in the gastrointestinal tract such as pepsin, trypsin, chymotrypsin and 84 
peptidases at the surface of epithelial cells to release peptides of various lengths. Some of these 85 
peptides may exert a direct function at the gastrointestinal tract. However, other peptides can be 86 
absorbed to reach target organs and tissues through systemic circulation [25].  87 
 In order to examine the effect of gastrointestinal proteases on the release of and 88 
breakdown of ACE inhibitory peptides from food proteins, simulated gastrointestinal digestion 89 
processes have been carried out on various protein sources, such as milk proteins (Table 1) [26-90 
30], egg proteins [11], meat proteins [31, 32], fish proteins [33, 34], as well as vegetal proteins 91 
[21, 35-37]. As an example, Hernandez-Ledesma et al., [28] identified peptides with ACE 92 
inhibitory and antioxidant activity in hydrolyzates of several samples of human milk and infant 93 
formulas after digestion with pepsin and pancreatin simulating infant gastrointestinal conditions. 94 
Recently, Majumder and Wu [38] have studied the effect of simulated gastrointestinal digestion 95 
of cooked eggs on the release of ACE inhibitory peptides. These authors found that fried egg 96 
digests showed more potent ACE inhibitory activity than boiled egg digests, and postulated that 97 
the lower protein denaturation in boiled eggs may results in a lower protein digestibility.  98 
 99 
2.2. Fermentation and maturation process 100 
During fermentation process, lactic acid bacteria (LAB) hydrolyze milk proteins, mainly 101 
caseins, into peptides and amino acids which are used as nitrogen sources necessary for their 102 
growth [39]. Hence, bioactive peptides can be generated by starter and non-starter bacteria used 103 
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in the manufacture of fermented dairy products (Table 1) [40-43]. Many of these peptides have 104 
been reported to exert ACE inhibitory and antihypertensive properties. Proteolytic system of 105 
Lactobacillus helveticus, Lactobacillus delbrueckii ssp. bulgaricus, Lactococcus lactis ssp. 106 
diacetylactis, Lactococcus lactis ssp. cremoris, and Streptococcus salivarius ssp. thermophylus 107 
strains have been demonstrated to hydrolyze milk proteins releasing ACE inhibitory peptides 108 
[reviews 3, 43, 44]. Some of the peptides identified also have been shown to lower blood 109 
pressure in hypertensive rats [45-47], and humans [48, 49]. The best characterized ACE 110 
inhibitory peptides are VPP and IPP found in milk fermented with Lactobacillus helveticus and 111 
commercialized in Japan (Calpis, Calpis Co. Ltd., Tokyo, Japan) and Finland (Valio Evolus 112 
Double Effect, Valio Ltd., Finland). This fermented milk has shown beneficial effects on blood 113 
pressure in several rat models and human studies [47, 48, 50-55]. 114 
Ashar and Chand [42] identified an ACE-inhibitory peptide from milk fermented with 115 
Lactobacillus delbrueckii ssp. bulgaricus, and Pihlanto et al. [56] reported two peptides 116 
responsible for the ACE inhibitory activity of milk fermented with Lactobacillus jensenii. In 117 
combination with Streptococcus salivarius ssp. thermophylus and Lactococcus lactis biovar. 118 
diacetylactis, a hypotensive structure with a sequence of SKVYP was obtained from β-casein. 119 
Quirós and co-workers [57] identified two peptides in fermented milk with Enterococcus faecalis 120 
that corresponded to -CN fragments LHLPLP and LVYPFPGPIPNSLPQNIPP, with potent 121 
ACE-inhibitory activity and proven antihypertensive effect when orally administered to 122 
spontaneously hypertensive rats after acute and long-term administration. 123 
During the maturation of cheese, the major milk proteins are degraded into a large number 124 
of peptides due to the action of endogenous milk enzymes, added coagulants and microbial 125 
enzymes. A number of studies have shown that ACE inhibitory peptides can be produced during 126 
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cheese making, in particular during ripening process. These peptides have been characterized in 127 
different commercial cheeses, such as Edam, Gouda, Camembert, Havarti and Blue cheese [58], 128 
Italian and Spanish cheeses [29, 59, 60], and Asiago cheeses [30]. Tri-peptides VPP and IPP have 129 
also been identified and quantified in different cheese varieties by Butikofer and co-workers [61, 130 
62]. A low-fat cheese containing ACE-inhibitory peptides derived from s1-casein and named as 131 
“Festivo” is commercialized in Eastern countries. 132 
Fermented soy products, traditionally consumed in Eastern countries, have been also 133 
found to be an important source of ACE-inhibitory and antihypertensive peptides. A potent 134 
antihypertensive peptide has been identified and characterized in a Korean soy product 135 
denominated “chunggugjang” and obtained by soy fermentation with Bacillus subtilis CH-1023 136 
[63]. Other ACE-inhibitory and antihypertensive peptides have been identified in soy paste [64], 137 
soy sauce [65, 66], natto and tempeh [67], and other fermented soy products [19, 68, 69].  138 
 139 
2.3. Enzymatic hydrolysis  140 
The most common way to produce bioactive peptides is through enzymatic hydrolysis of 141 
whole protein molecules (Table 1). A large number of studies have demonstrated the release of 142 
ACE inhibitory and/or antihypertensive peptides from food proteins, by hydrolysis with 143 
gastrointestinal enzymes, such as pepsin, trypsin, and chymotrypsin [24, 70-72]. Manso and 144 
Lopez-Fandino [73] described occurrence of ACE-inhibitory peptides in hydrolyzates of bovine, 145 
ovine and caprine κ-casein upon hydrolysis with various digestive enzymes. Pepsin was used by 146 
Contreras and co-workers [74] to hydrolyze total isoelectric casein and three peptide sequences 147 
derived from αs1-casein and αs2-casein were characterized as ACE inhibitors and antihypertensive 148 
peptides.  149 
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In addition to live microorganisms, proteolytic enzymes from bacterial and fungal sources 150 
have been used to generate bioactive peptides from various proteins. The use of commercially 151 
available microbial-derived food grade proteinases to hydrolyze food proteins is advantageous as 152 
these enzymes are low-cost and safe, and the product yields are very high [75]. Ueno et al. [76] 153 
purified and characterized an endopeptidase from Lb. helveticus CM4 and demonstrated that this 154 
peptidase can generate antihypertensive peptides using synthetic pro-peptides as substrates. 155 
Mizuno et al. [77] measured the ACE-inhibitory activity of casein hydrolyzates upon treatment 156 
with nine different commercially available proteolytic enzymes. Among these enzymes, a 157 
protease extracted from Aspergillus oryzae acted specifically on casein to release VPP and IPP, 158 
and the obtained casein hydrolyzate demonstrated a significant dose-dependent antihypertensive 159 
effect in a rat model with spontaneously hypertensive rats.  160 
Recently, the interest of food technologists has turned to the use of different techniques, 161 
such as high-pressure and heat denaturing and power ultrasound to modify protein structure and 162 
increase enzymatic hydrolysis. As compared to the proteolysis at atmospheric pressure, 163 
qualitative and quantitative differences were detected in the hydrolysis pattern when proteolysis 164 
with trypsin was carried out under high pressure treatments [78-79]. Hernandez-Ledesma et al. 165 
[80] reported that heating of -Lg during enzyme treatments with thermolysin enhances the 166 
formation of peptides with ACE-inhibitory activity, and one of the peptides released under these 167 
heat-denaturing conditions was LQKW that had previously been described as a potent ACE 168 
inhibitor [81]. Prolonged exposure to high-intensity ultrasound has been shown to inhibit the 169 
catalytic activity of a number of food enzymes [82]. However, in some cases, solutions 170 
containing enzymes have been found to have increased activity following short exposures to 171 
ultrasound [83]. Jia et al. [84] found that the use of ultrasonic treatment during proteolysis could 172 
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facilitate the enzymatic hydrolysis of peptide DWGP, whereas ultrasonic pre-treatment could 173 
promote the release of ACE inhibitory peptides from this peptide. 174 
 175 
2.4. Genetic recombination in bacteria 176 
Industrial preparation of ACE inhibitory and/or antihypertensive peptides by enzymatic 177 
hydrolysis and microbial fermentation showed to be a low efficient process because of low yield 178 
and high cost of separation and purification processes [85-88]. To solve these issues, during last 179 
years a new technique based on genetic engineering is being developed. One of the challenges of 180 
this technique is the susceptibility of short antihypertensive peptides to degradation by protease 181 
or peptidase. Moreover, the expression products may be harmful to the host, impacting the high-182 
level expression of the gene. This shortcoming has been conquered by expression of 183 
antihypertensive peptides in the forms of a fusion protein or a tandem gene. Antihypertensive 184 
peptides with sequences HHL, HVLPVP, FFVAPFPEVFGK, and GHIATFQER have been 185 
expressed successfully in Escherichia coli [89-92], although special proteases are needed to 186 
release the target active protein, thus increasing the cost of separation and purification after 187 
enzymatic hydrolysis. Recently, Rao et al. [93] expressed an antihypertensive peptide multimer, a 188 
common precursor of 11 kinds of antihypertensive peptides, and the release was confirmed by 189 
simulated gastrointestinal digestion. Because of the fact that currently genetic modified 190 
microorganisms are difficult to be used in food products, further studies should be needed.  191 
 192 
3. In vitro and in vivo assays 193 
The search for ACE inhibitory activity is the most common strategy followed in the 194 
selection of antihypertensive peptides derived from food proteins. In order to study ACE 195 
inhibition, simple, rapid, sensitive and reliable analytical methods are desirable. In vitro 196 
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inhibitory activity is generally measured by monitoring the conversion of an appropriate substrate 197 
by ACE in the presence and absence of the potential inhibitors. There are several methods, but 198 
those based on spectrophotometric and high-performance liquid chromatography (HPLC) assays 199 
are most commonly utilized. The spectrophotometric method of Cushman and Cheung [94] is 200 
based on the hydrolysis of Hippuryl-His-Leu (HHL) by ACE to hippuric acid and His-Leu, and 201 
the extent of hippuric acid released is measured after its extraction with ethyl acetate. The 202 
inhibitory potency is expressed as the IC50 value, or concentration needed to inhibit 50% of the 203 
enzyme activity. Extraction of reaction product is tedious and may overestimate ACE activity if 204 
unhydrolyzed HHL is also extracted. Another broadly used spectrophotometric method is based 205 
in the hydrolysis of a furanocryloyl tripeptide (FAPGG) to FAP and the di-peptides GG [95]. 206 
Using HPLC methods, the peak of hippuric acid may be interfered with by the added ACE 207 
inhibitors in the reaction mixture, so the mobile phase needs to be adjusted to different tested 208 
compounds. Moreover, the HPLC method show lower detection sensitivity and longer analysis 209 
time to obtain good results. Doig and Smiley [96] and Mehanna and Dowling [97] have improved 210 
HPLC methods by applying ultraviolet detection, and Van Elswijk et al. [98] have developed an 211 
alternative strategy for the screening of complex food samples applying an HPLC method with 212 
biochemical detection. In that approach, separation and activity detection are combined within 213 
one step. However, as spectroscopic detection is used to monitor the enzymatic conversion, these 214 
methods are restricted to artificial substrates as well. Direct, extraction-free methods have been 215 
published recently [99, 100]. Siemerink et al. [101] have optimized a new robust HPLC coupled 216 
with electrospray ionization mass spectrometry (HPLC/ESI-MS)-based screening method for 217 
ACE-inhibiting substances in crude samples. Similarly, an ultra-performance-liquid 218 
chromatography (UPLC) coupled with MS (UPLC-MS) for determination of the ACE activity 219 
has been recently developed by Geng et al. [102]. This new method is more sensitive, accurate 220 
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and reproducible. The small total reaction volume, the short analysis time, high selectivity and 221 
lower expense are the advantages of this method in comparison with the conventional methods.  222 
The antihypertensive effects can only be reliably assessed by in vivo experiments using 223 
spontaneously hypertensive rats that constitute an accepted model for human essential 224 
hypertension [7]. A great number of studies have addressed the effects of both short-term and 225 
long-term administration of potential antihypertensive peptides using this animal model [88, 103-226 
106]. Moreover, many in vivo studies include the evaluation of the effect of antihypertensive 227 
peptides on arterial blood pressure of normotensive Wistar-Kyoto rats. Recently, Nakahara et al. 228 
[66] have used the Dahl salt-sensitive rats as a model of salt-sensitive hypertension to evaluate 229 
the antihypertensive effect of a peptide-enriched soy-sauce like seasoning. The results of these 230 
tests have highlighted an important lack of correlation between the in vitro ACE inhibitory 231 
activity and the in vivo action. This fact has provided doubts on the use of the in vitro ACE 232 
inhibitory activity as the exclusive criteria for potential antihypertensive substances because other 233 
mechanisms of action than ACE inhibition might be responsible for the antihypertensive effect. 234 
Also, it should be needed to take into consideration the physiological transformations 235 
determining the bioavailability of the peptides.  236 
 The antihypertensive effect of some food proteins-derived peptides has been conducted in 237 
human studies to determine whether these peptides posses an antihypertensive effect on human 238 
subjects with high-normal blood pressure and mild hypertension [50, 107, 108]. The most 239 
substantiated antihypertensive activity in humans has been obtained for the commercial 240 
fermented milk products and hydrolyzates containing the ACE-inhibitory peptides IPP and VPP. 241 
The antihypertensive effect of the sour milk product Calpis, commercialized in Japan, was tested 242 
in a clinical study with mildly hypertensive patients [50]. Recently, a study has been conducted 243 
among patients with high-normal blood pressure and mild hypertension, evaluating the effect of 244 
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different doses of a casein hydrolyzate produced by Aspergillus oryzae containing IPP and VPP 245 
and commercialized as AmealPeptide
®
 by Calpis [77]. Similarly, a milk product Evolus
®
 246 
fermented with Lactobacillus helveticus LBK-16H and produced by Valio Ltd. (Finland) has 247 
been tested in hypertensive humans [48]. This product, containing peptides IPP and VPP, showed 248 
to exert a long-term blood pressure-lowering effect after normal daily ingestion during a 21- 249 
weeks intervention period.   250 
 251 
4. Structure-activity relationship 252 
Although the structure-activity relationship of ACE-inhibitory peptides derived from 253 
foods has not yet been fully elucidated, several structural features influencing potency of these 254 
peptides have been identified [7, 109]. Recently, it has been reported that artificial neural 255 
networks (ANN) and quantitative structure-activity relationship (QSAR) modelling may be used 256 
to develop statistical computer models potentially capable of identifying ACE inhibitory peptides 257 
based on structure-activity data [110]. Several descriptor variables such as molecular mass and 258 
shape, hydrophobicity, charge and electronic properties have been recognized as critical in this 259 
QSAR modelling. The majority of ACE inhibitory peptides are relatively short sequences 260 
containing from 2 to 12 amino acids. This in agreement with the results of Natesh and coworkers 261 
[111], which demonstrated from crystallography studies, that the active site of ACE cannot 262 
accommodate large peptide molecules. However, some studies have identified ACE inhibitory 263 
peptides with up to 27 amino acids [58, 112, 113]. Of many ACE-inhibitory peptides identified 264 
from different food sources, structure-activity correlation indicated that C-terminal tri-peptide 265 
residues play a predominant role in competitive binding to the active site of ACE. It has been 266 
reported that this enzyme prefers substrates or inhibitors containing hydrophobic (aromatic or 267 
branched side chains) amino acid residues at each of the three C-terminal positions. The most 268 
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effective ACE inhibitory peptides identified contain Tyr, Phe, Trp, and/or Pro at the C-terminal. 269 
Gomez-Ruiz and coworkers [29] have suggested that amino acid Leu may contribute 270 
significantly to increase ACE inhibitory potential. Furthermore, other branched chain aliphatic 271 
amino acids such as Ile and Val are predominant in highly peptide inhibitors. In addition, 272 
structure-activity data suggest that the positive charge of Lys ( -amino group) and Arg (guanidine 273 
group) as the C-terminal residue may contribute to the inhibitory potency [114-117]. Other 274 
characteristics have also been found to play important roles for ACE inhibition. It has been 275 
recognized that ACE inhibitory peptides possess a characteristic pattern (i.e. a similar positive 276 
potential located at the C-terminal end) different from that of inactive peptide molecules [112, 277 
118]. For long chain peptides, it is expected that peptide conformation, i.e. the structure adopted 278 
in the specific environment of the binding site, will influence binding to ACE [117, 118]. It has 279 
also been demonstrated that ACE has a requirement for the L-configuration of the amino acid at 280 
position three from the C-terminal. Moreover, changes in cis-trans conformations of Pro at the C-281 
terminal position of an ACE inhibitory peptide may cause significant changes in its interaction 282 
with the enzyme [119].  283 
 284 
5. Mechanism of action 285 
 Blood pressure is determined by cardiac output and vascular peripheral resistance, and is 286 
regulated by a complex system involving the RAS, the sympathetic nervous system (SNS), and 287 
the kidney and fluid balance mechanism [118]. Most food-derived peptides usually display 288 
higher in vivo activities than the efficacy levels extrapolated from the in vitro ACE inhibitory 289 
activity. This may be an indication of the existence of an additional mode of action [120]. In fact, 290 
increasing evidence is being provided that different mechanisms, others than ACE inhibition, are 291 
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involved in the blood-pressure-modulating effect exerted by many of these peptides. In vitro, tri-292 
peptides VPP and IPP have been shown to inhibit ACE at micromolar concentrations [40, 41]. In 293 
vivo, long-term treatment of spontaneously hypertensive rats with fermented milk containing 294 
these peptides has been found to decrease serum ACE activity [121-123]. However, according to 295 
Jauhiainen et al. [54], the mechanistic theory of ACE inhibition of IPP and VPP remains to be 296 
confirmed and other effects have to be taken into consideration. Some of these effects have been 297 
evaluated in animal models and clinical studies. Plasma rennin activity and levels have been 298 
found to be raised in spontaneously hypertensive rats receiving IPP and VPP for 14 weeks. This 299 
raising can be due to the lack of negative feedback by angiotensin II, which supports that ACE 300 
was inhibited [47]. Other authors have reported the protective effects exerted by these peptides on 301 
endothelial function of isolated mesenteric arteries of rats after 24 h incubation with them [124]. 302 
In humans with mild hypertension, administration of a casein hydrolyzate containing VPP and 303 
IPP increases maximum blood flow forearm during reactive hyperemia, thus demonstrating an 304 
improvement in the vascular endothelial dysfunction. Yamaguchi et al. [125] studied effect of a 305 
5-day repeated administration of VPP and IPP on gene expression of spontaneously hypertensive 306 
rats abdominal aorta using DNA microarray microanalysis, reporting a significant increase for the 307 
endothelial nitric oxide synthase (eNOS) gene and the connexion 40 gene, which are involved in 308 
blood pressure regulation. Expression of these genes was restored in the aortic tissue after 309 
treatment with these tri-peptides [126, 127], suggesting that VPP and IPP might act in vivo as 310 
ACE inhibitors in the aorta and also have preventive potential in cardiovascular function.  311 
Fuglsang et al. [46] reported that ingestion of two milks fermented with Lactobacillus 312 
helveticus provokes a decrease of the response to an intravenous injection of angiotensin I in 313 
unconscious normotensive rats, whereas response to bradikinin was increased, confirming the 314 
inactivation of ACE. Dried bonito-ACE inhibitory peptides slightly inhibit angiotensin I-induced 315 
 15 
contractions in rat-isolated aorta as compared with Captopril, but unlike this drug, peptides exert 316 
a direct action on vascular smooth muscles [128]. Similarly, peptide lactokinin (ALPMHIR) 317 
inhibits the release of ET-1, an endothelial factor that evokes contractions in smooth muscle cells 318 
through mechanisms both dependent and independent of ACE-inhibition [129]. It is also likely 319 
that opioid receptors are involved in the antihypertensive effect of some peptides, such as α-320 
lactorphin, β-lactorphin and human casein-derived fragments, as this was abolished by the opioid 321 
receptor antagonist naloxone. As an example, it has been demonstrated that α-lactorphin, a tetra-322 
peptide (YGLF) formed by in vitro proteolysis of α-lactalbumin with pepsin and trypsin, lowers 323 
blood pressure in spontaneously hypertensive rats and produces an endothelium-dependent 324 
relaxation of their mesenteric arteries that is inhibited by an eNOS inhibitor [47]. Therefore, a 325 
mechanism of action driven by the stimulation of peripheral opioid receptors and subsequent 326 
nitric oxide (NO) release causing vasodilation has been proposed for this peptide. Although -327 
lactorphin interacting with opioid receptors does no elicit effects typical of centrally active 328 
opioids such as antinociception and sedation [130]. It has been suggested that these opioid 329 
peptides might lower blood pressure through receptors expressed in the gastrointestinal tract, 330 
which implies that no absorption is required [131].  331 
 Strong epidemiological evidence indicates that oxidative stress and associated oxidative 332 
damage are mediators in cardiovascular diseases. In experimental and human hypertension 333 
studies, it has been demonstrated an increased production of superoxide anion and hydrogen 334 
peroxide, reduced NO synthesis, and decreased bioavailability of antioxidants [132]. Therefore, 335 
food-derived peptides with antioxidant properties might also have effect on blood pressure 336 
modulation. Many of these peptides have been identified and characterized from casein and whey 337 
proteins hydrolyzed with different enzymes [133, 134]. 338 
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Taking together the results of all these studies, more thorough mechanistic research 339 
should be probably needed to detect the changes in the factors affecting blood pressure and 340 
vascular tone to show the exact mechanisms also in vivo of antihypertensive peptides.  341 
 342 
6. Bioavailability and clinical studies 343 
The physiological effects of bioactive peptides depend on the ability to reach in an active 344 
form their target organs. This implies resistance to gastrointestinal enzymes and brush border 345 
membrane peptidases and absorption through the intestinal epithelium. The resistance of peptides 346 
to these processes is usually performed by sequential hydrolysis with pepsin and pancreatic 347 
extracts mimicking the gastrointestinal conditions and with in vitro studies with epithelial 348 
intestinal cells. Although peptides were though to be rapidly metabolized to constituent amino 349 
acids, these studies have demonstrated that several peptides are resistant to these physiological 350 
processes and can reach the circulation. This is the case of the short tri-peptides IPP and VPP 351 
[135, 136], but also has been demonstrated for longer proline-rich peptides, such as, LHLPLP. 352 
This latter peptide resists simulated gastrointestinal digestion but it is hydrolysed to a shorter 353 
active form, HLPLP, by cellular peptidases prior to transport across the intestinal epithelium [137, 354 
138]. Figure 1 shows the formation of the shorter peptide during incubation of the peptide 355 
LHLPLP in the apical chamber of the Caco-2 cell culture. The penta-peptide appeared in 356 
approximately 3 min and its concentration increased with the incubation time up to 60 min. This 357 
shorter form has also been detected in human plasma after oral administration which 358 
demonstrates intestinal absorption of the pentapeptide in humans [139]. In some cases, the active 359 
form is released during gastrointestinal processes. For instance, the active form of peptide 360 
KVLPVPQ is generated by hydrolysis of the glutamine residue at the C-terminal end during 361 
pancreatic digestion [140]. This is also the case of the egg-derived antihypertensive peptides 362 
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YAEERYPIL and RADHPFL that were hydrolysed to other active forms after simulated 363 
gastrointestinal digestion [11]. The pharmacokinetic behaviour of the tri-peptides IPP and VPP 364 
has also been studied and an absolute bioavailability of 0.1% respect the administered dose has 365 
been calculated in pigs [141]. In humans, these two tri-peptides were detected in plasma after oral 366 
administration at picomolar concentrations and their absorption was enhanced when ingested in 367 
the form of an enriched yogurt beverage. In addition, a further increase (1.2-fold) in the plasmatic 368 
concentration of IPP was found when the enriched yogurt was administered after a meal [142]. 369 
Several clinical studies have evaluated the antihypertensive effect of the tri-peptides IPP 370 
and VPP after long-term administration in humans. Most of them are included in two meta-371 
analyses recently published [143, 144]. The meta-analysis by Xu et al. [143] includes 12 trials 372 
with a total of 623 participants and found significant decreases in systolic and diastolic blood 373 
pressure (4.8 mmHg and 2.2 mmHg, respectively). Similar results arose from the meta-analysis 374 
published by Pripp et al. [144] with a total of 15 clinical trials included. Although two long-term 375 
studies have not found statistical differences with these tri-peptides [145, 146], most recent 376 
reviews on the subject identify several factors such as component of the final product, dose, 377 
method for blood pressure measurement that can influence the results in different trials [147, 148]. 378 
 379 
7. Incorporation into food products 380 
For an industrial application of protein hydrolyzates containing antihypertensive peptides, 381 
main considerations would be the organoleptic characteristics of these ingredients and the 382 
evaluation of the resistance of the active peptides to processing conditions. The practical use of 383 
protein hydrolyzates in food systems is hindered due to the presence of low molecular weight 384 
peptides composed mainly of hydrophobic amino acids that results in a bitter taste [149]. In fact, 385 
this problem has limited the use of some of the developed hydrolyzates with proved 386 
 18 
antihypertensive effect. In addition to the bitterness, the pH of the hydrolysis reaction needs to be 387 
regulated because the substrate susceptibility and the enzyme activity are strongly influenced by 388 
the pH. In order to achieve the desired hydrolysis degree to obtain biologically active peptides, 389 
the addition of some alkali or acid is required to neutralize the hydrolysis products. This leads to 390 
undesirable high ash build up in the hydrolyzates and the development of salty off-flavors. 391 
Different strategies have been applied for debittering protein hydrolyzates. These include 392 
absorption of bitter peptides on activated carbon, chromatographic removal using different 393 
matrices and selective extraction with alcohols [149]. The most extended approaches include 394 
hydrolysis of bitter peptides with enzymes such as aminopeptidase, alkanine/neutral protease and 395 
carboxypeptidase, condensation reactions of bitter peptides using protease and use of 396 
Lactobacillus as debittering starter adjunct [150]. However, the application of all these methods 397 
in biologically active hydrolyzates is limited because the enzymatic activity used for debittering 398 
can hydrolyze the previously generated bioactive peptides. Although it has not been found a 399 
significant correlation between bitterness and the ACE-inhibitory activity of di- and tri-peptides 400 
[151], it is recognized the importance of hydrophobic amino acid residues for both bitterness and 401 
ACE-inhibitory peptides. Therefore, those methods based in the removal of bitter peptides (either 402 
absorption, extraction or hydrolysis) have to be carefully applied to hydrolyzates containing, for 403 
instance, ACE-inhibitory peptides. For bioactive hydrolyzates, the application of masking 404 
methods by using monosodium glutamate or glutamylglutamic acid [152], the addition of 405 
cyclodextrins [153], encapsulation [154], or the addition of phospholipids and lysophopholipids 406 
[155] could be preferably used. For instance, for the encapsulation of casein hydrolyzates, 407 
different materials such as soy proteins isolates alone or in mixtures with gelatin [154, 156], 408 
maltodextrins [157], or lipospheres [158] have been successfully applied. The presence of 409 
proteins and reducing carbohydrates in a food ingredient will lead to the formation of Maillard 410 
 19 
compounds that can have a positive effect on flavor but this reaction has to be controlled to avoid 411 
the generation of undesirable compounds [159, 160]. Therefore, the improvement of the flavor of 412 
biologically active protein hydrolyzates including possible protein-flavor interactions and the 413 
effect of these processes on biological activity are of interest in relation to the development of 414 
novel protein foods. 415 
Processing provides an additional value to foods in improving their safety, shelf-life, 416 
palatability, nutritive and functional value, but the conditions of processing and storage may be 417 
detrimental to peptides. At this regard, changes in the molecular structure of an amino acid may 418 
lead to changes in the bioactivity and in the absorption of the peptide of interest. The most 419 
relevant degradation pathways of amino acids during processing were recently reviewed by 420 
López-Fandiño & co-workers [3]. For example, thermal processing favors racemization, amino 421 
acids decomposition (e.g. ornithine from arginine), glycation (non-enzymatic browning or 422 
Maillard reaction), and cross-linking. Furthermore, amino acids can be also oxidized during food 423 
processing [161], and even D-amino acids can by synthesized out from L-amino acids by LAB. 424 
Dehydratation by spray-drying may produce some negatively effects on food protein 425 
hydrolyzates, such as changes in peptide composition, reduction of amino acid content and non 426 
enzymatic browning [162-164]. There are little data about the effects of other processes on 427 
bioactive peptides. Recently, the stability of two s1-casein-derived antihypertensive peptides to 428 
spray-drying, homogenization and pasteurization when they were incorporated into fermented 429 
milk has been demonstrated [165]. Incorporation of active hydrolyzates to fermented milks 430 
implies that these peptides have to survive in the presence of LAB because of their cell-431 
associated proteinases/peptidases systems that could further hydrolyze the bioactive sequences. 432 
For instance, it has been reported that an 12 amino acid long antihypertensive peptide can be 433 
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digested by exposure to yogurt starter culture strains and therefore, the incorporation of this 434 
bioactive peptide should preferably done at the end of the yogurt-making process [166]. 435 
 436 
8. Future prospects 437 
Among the different groups of bioactive peptides defined, antihypertensive peptides have 438 
received special attention, their activity has been tested in vitro, animal models and humans, and 439 
they have been incorporated into different food products. Controversial results on clinical studies 440 
and the different health claim legislations will contribute to increase research in this area. In this 441 
sense, different studies have been performed to demonstrate stability of the peptide, absorption 442 
and identification of the active form in the organism. It has been postulated that physiologically 443 
relevant concentrations and elimination kinetics will be mandatory for food derived bioactive 444 
components as it is now for pharmaceutical compounds. At the same time, the recent advances on 445 
specific analytical techniques able to follow small amounts of the peptides or derivatives from 446 
them in complex matrices and biological fluids will allow performing these kinetic studies in 447 
model animals and humans. Similarly, advances in new disciplines such as nutrigenomic and 448 
nutrigenetic will open new ways to follow bioactivity in the organism by identifying novel and 449 
more complex biomarkers of exposure and/or of activity. All these advances will be done 450 
simultaneously with the knowledge food technologists since the final formulation of the food 451 
product is crucial to ensure activity and bioavailability of bioactive peptides. 452 
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Figure captions 459 
Figure 1: Changes of the synthetic peptide LHLPLP when added to apical chamber of a Caco-2 460 
cell culture at different periods of time. Extracted ion chromatograms obtained by HPLC-MS 461 
analysis of the apical chamber after a) 5 min, b) 10 min, c) 30 min, and d) 60 min of incubation. 462 
The extracted ion chromatogram was obtained by extraction of ions with m/z 689.4, 711.4 and 463 
727.4, which correspond to molecular ion of peptide LHLPLP and its sodium and potassium 464 
adducts, and ions with m/z 598.3, 614.3 and 620.3, corresponding to molecular ion of peptide 465 
HLPLP and its sodium and potassium adducts. Reproduced from [137] with permission. 466 
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Table 1. ACE inhibitory and antihypertensive activity in spontaneously hypertensive rats of peptide derived from caseins and whey proteins by fermentation 921 
and enzymatic hydrolysis 922 
 923 
 924 
Peptide Sequence
 
IC50 ( M)
a
 Decrease of 
SBP (mmHg)
b
 
Origin Reference 
s1-CN f(1-9) RPKHPIKHQ 13.4 -9.3 Gouda cheese  [58] 
s1-CN f(146-147) YP 720 -32.1
 
Fermentation with Lb. helveticus CPN4 [140] 
-CN f(58-76) LVYPFPGPIPNSLPQ
NIPP 
5.2 -15.0
 
Fermentation with En. faecalis [11, 57] 
-CN f(60-68) YPFPGPIPN 14.8 -7.0
 
Gouda cheese  [58] 
-CN f(74-76) IPP 5.0 -28.3 (-10.1)
d 
Fermentation with Lb. helveticus y Sc. cerevisiae [40, 41] 
-CN f(84-86) VPP 9.0 -32.1 (-10.1)
d 
Fermentation with Lb. helveticus y Sc. cerevisiae [40, 41] 
-CN f(133-138) LHLPLP 5.5 -21.9 Fermentation with En. faecalis [11, 57] 
-CN f(133-139) LHLPLPL 425 -7.7 Fermentation with En. faecalis [11, 57] 
-CN f(197-206) VLGPVRGPFP 137 -16.2 Fermentation with En. faecalis [11, 57] 
-CN f(201-209) VRGPFPIIV 599 -16.1 Fermentation with En. faecalis [11, 57] 
s1-CN f(23-34) FFVAPFPGVFGK 77 -34.0 Hydrolysis with trypsin [167] 
s1-CN f(104-109) YKVPQL 22 -13.0
 
Hydrolysis with a proteinase from Lb. helveticus CP790 [140] 
s1-CN f(194-199) TTMPLW 16 -13.6 Hydrolysis with trypsin [167] 
s2-CN f(189-192) AMPKPW 580 -5.0 Hydrolysis with a proteinase from Lb. helveticus CP790 [140] 
s2-CN f(190-197) MKPWIQPK 300 -3.0 Hydrolysis with a proteinase from Lb. helveticus CP790 [140] 
s2-CN f(198-202) TKVIP 400 -9.0 Hydrolysis with a proteinase from Lb. helveticus CP790 [140] 
s2-CN f(203-208)
d
 PYVRYL 1.9 23.4 Hydrolysis with pepsin [168] 
-CN f(59-61) VYP 288 -21.0
 
Hydrolysis with proteinase K [169] 
-CN f(59-64) VYPFPG 221 -22.0
 
Hydrolysis with proteinase K [169] 
-CN f(80-90) TPVVVPPFLQP 749 -8.0
 
Hydrolysis with proteinase K [169] 
-CN f(140-143) LQSW 500 -2.0
 
Hydrolysis with a proteinase from Lb. helveticus CP790 [140] 
-CN f(169-174) KVLPVP 5 -32.2
 
Hydrolysis with a proteinase from Lb. helveticus CP790 [140] 
-CN f(169-175) KVLPVPQ 1000 -31.5
 
Hydrolysis with a proteinase from Lb. helveticus CP790 [140] 
 925 
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Table 1. (Continuation). ACE inhibitory and antihypertensive activity in spontaneously hypertensive rats of peptide derived from caseins and whey proteins 926 
by fermentation and enzymatic hydrolysis 927 
 928 
 929 
Peptide Sequence
 
IC50 ( M)
a
 Decrease of 
SBP (mmHg)
b
 
Origin Referente 
-CN f(177-183) AVPYPQR 15 -10.0
 
Hydrolysis with trypsin [167] 
-La f(50-53) YGLF 733 -23.0
 
Hydrolysis with gastric and pancreatic enzymes [170] 
-Lg f(58-61)
e
 LQKW 34.7 -18.1 Hydrolysis with thermolysin [103] 
-Lg f(78-80) IPA 141 -31.0 Hydrolysis with proteinase K [169] 
-Lg f(103-105)
e
 LLF 79.8 -29.0
 
Hydrolysis with thermolysin [104] 
BSA f(221-222) FP 315 -27.0 Hydrolysis with proteinase K [169] 
 930 
 931 
 
a
: Peptide concentration needed to inhibit 50% ACE activity 932 
b
: Systolic blood pressure 933 
c
: Antihypertensive effects in humans  934 
d
: Ovine protein 935 
e
: Caprine protein 936 
 937 
 938 
 939 
